



VOLUME 65, 2000 KEYWORD INDEX

- Accumbens, 369
Accumbens core, 203
Accumbens shell, 203
ACEA-1021, 611
Acetylcholine, 369, 519
Acetylcholine release, 375
Acoustic startle, 691
Acquisition, 697
Acute administration, 339
Adenosine, 155
Adrenergic agents, 275
Adrenergic receptors, 255
Aging, 321, 665
Allocentric place discrimination task, 131
 α_5 subunits, 743
AMPA, 67
Amphetamines, 203, 407, 419, 585, 655
d-Amphetamines, 43
Amygdala, 35, 591
Analgesia, 61, 97, 563, 621
Animal models, 539
Anorexia, 531
Antagonists, 313
Antibody, 191
Antidepressants, 1, 339, 591, 737
Antinociception, 61, 97, 261
Antisera to opioid peptides, 217
Anxiety, 7, 199, 351, 539, 571
Anxiety-like behavior, 267
Anxiety peptide, 123
Anxiogenic compound, 7
Anxiogenic-induced behavior, 649
Anxiolytic, 465
Anxiolytic effect, 627
Anxiolytic-like activity, 339
Apomorphine, 275, 389, 449
Appetite, 369, 381
Areca catechu, 1
Arousal, 495
2-Aryl-2,5-dihydropiridazino[4,3-b]-indol-3(3H)ones, 475
Attention, 665
Audigenic seizures, 475
Autoshaping, 509
Avian, 67
Avoidance behavior, 539
BALB/c mice, 35, 419, 465
Basal ganglia, 439
Behavior, 123, 175
Behavioral sensitization, 241
Benzodiazepine receptor agonists, 105
Benzodiazepines, 35, 223, 351, 705
binding site of the GABA_A receptors, 313
binding sites, 743
1,4-Benzodiazepines, 475
Beta-carbolines, 737
Bicuculline, 223
Biological rhythms, 289
Blood pressure, 191
Bromocriptine, 503
Brown fat, 719
BSL behavior, 621
Buspirone, 281
C57 mice, 145
Caffeine, 655
Calmidazolum, 621
 β -Carbolines, 475
Catalepsy, 503
C57BL/6 mice, 35, 419
C57BL/6J mice, 301
 β -CCE, 267
CCK, 459
CDP, 105
Celiprolol, 719
Cell damage, 23
Central injection, 123
Central muscarinic system, 131
Cerebral protection, 23
Challenge, 389
Chemical model, 577
Chicks, 223
Chloroquine, 333
Choline, 519
Choline oxidase, 519
Cholinergic, 163
Cholinesterase, 175
Cholinomimetic-induced tremulous jaw movements, 683
Chronic pain, 141
Chronopharmacology, 289
Cingulate cortex, 363
Circadian rhythms, 155, 495, 585
cis-Fluphenthixol, 433
Classical conditioning, 83
Clonazepam, 705
Cocaine, 43, 83, 255, 289, 419, 659
Cocaine discrimination, 671
Cocaine-induced toxicity, 677
Cognitive function, 247
Conditioned fear, 301
Conditioned flavor preference, 635
Conditioned place preference, 281, 327, 419, 697
Conditioned suppression, 83
Conflict behavior, 731
Convulsions, 333
Cortex, 711
Corticosterone, 233, 509
Cortisol, 123, 539
CPP, 621
d-CPPEne (SDZ EAA 494), 611
Crack cocaine, 255
Craving, 369, 489
CRH, 123
Crotalus durissus terrificus venom, 7
Crotalus durissus terrificus venom, 7
Crotoxin, 7
Cue, 489
Cynomolgus monkeys, 503
D₁ receptors, 635
D₂ receptors, 203, 495, 635
Dantrolene, 439
DBA/2 mice, 475
DBA/2J, 301
Delayed nonmatching-to-position task, 725
Depression, 539, 591
Development, 449
DHPG PHCCC, 439
Diazepam, 223, 281, 351, 731
Dichloromethane fraction, 1
5,7-Dihydroxytryptamine, 15
Diphenhydramine, 683
Discrimination, 31, 489
Diuresis, 53
Dizocilpine (MK-801), 611
L-DOPA, 503
Dopamine, 433, 439, 509, 635, 659
Dopamine agonists, 495
Dopamine antagonists, 671
Dopamine D₃ receptors, 31, 241
Dopamine turnover, 389
Dopaminergic, 163
Doxepin, 683
7-OH-DPAT, 31, 241
8-OH-DPAT, 183
D₂ receptors, 547
Drinking, 375
Drinking behavior, 719
Drug abuse, 369, 509, 655
Drug discrimination, 43
Drug-induced stimulus control, 75
Drug interactions, 43
EAA494 NMDA antagonists, 725
Eating, 375
EEG, 577, 711
EGb 761, 321
Elevated plus-maze, 15, 209, 267
Elevated T-maze, 571
Elevated zero-maze, 737
Eliprodil, 611
EMG, 117
Enadoline, 43
Environment, 389
Ephedrine, 655
Epilepsy, 475, 547
Ethanol, 281, 345, 357
Ethanol discrimination, 145
Ethanol reward, 145
Ethanol withdrawal, 345
Ethological analysis, 209
Eticlopride, 203
Event-related potentials, 711
Exploration, 7

- Exploratory, 433
 Exploratory activity, 737
 Expression studies, 635, 697
 Extinction, 399
 Fear conditioning, 691
 Fear-potentiated startle, 301
 Feeding, 183, 369, 433
 Feeding behavior, 381, 719
 Fenfluramine, 369
 Fentanyl, 563
 Flavonoids, 313
 Flumazenil, 223, 475, 705
 Fluoxetine, 209
 Food intake, 67, 97, 381, 531
 Foot shock, 363
 Forced-swim test, 591
 Four-plate test, 339
 GABA, 223, 705
 GABA-benzodiazepine receptors, 627
 GABA transporter, 351
 GABA_A-receptors, 731, 743
 Gender, 53, 91
 Genetics, 301
 Gepirone, 209
 Gerbils, 599
 Gingko biloba, 321
 Glutamate, 67, 345
 Glutamate receptors, 627
 Guinea pig, 175
 H1 antagonists, 683
 Hamster, 585
 Harmaline, 117
 Herbal dietary supplements, 655
 High-performance liquid chromatography, 289
 Hippocampus, 15, 547, 711
 Histamine, 61
 Holeboard, 7
 HPA axis, 591
 5-HT, 1
 5-HT₃ antagonists, 145
 5-HT-receptor antagonists, 531
 5-HT transporter, 233
 5-HT_{1A}, 75, 183
 5-HT_{2A}, 75
 5-HT_{1A} receptors, 233
 Humans, 599
 Hydroxyl radicals, 425
 5-Hydroxytryptamine, 1, 75, 145, 183, 233, 531
 Hyperalgesia, 141, 261
 Hypericin, 627
Hypericum, 627
 Hypokinesia, 523
 Hypothermia, 23, 389
 Ibotenate, 163
 Imipramine, 571
 Immediate-early gene NGFI-A, 399
 Immunization, 191
 Improgan, 61
 Impulsivity, 731
 Inbred mice, 301, 399
 Individual differences, 509
 Intact male mice, 327
 Interleukin-1, 531
 Interstimulus interval, 83
 Kainic acid, 39
 Kappa opioid receptors, 97
 Kappa opioids, 53
 Kindling, 23, 743
 [³H]L-655, 708, 743
 Labetalol, 255
 Latent inhibition, 459
 Lateral hypothalamus, 183
 Learning, 233, 519
 Lesion, 267
 Lever press, 509
 Lewis, 357
 Licking, 275
 Lidocaine, 117
 Light, 585
 Light-dark aversion test, 649
 Light/dark choice procedure, 465
 Lipolysis, 719
 Lithium, 547
 Locomotor activity, 191, 241, 281, 389, 433, 495, 539, 585
 Locomotor behavior, 627
 Macronutrient intake, 381
 Male and female rats, 671
 Marking behavior, 539
 Mazes
 elevated plus-maze, 15, 209, 267
 elevated T-maze, 571
 elevated zero-maze, 737
 MCAO, 553
 MDL 11939, 677
 MDL 72222, 145
 Mechanisms, 577
 Median raphe nucleus, 15
 Mediating behavior, 725
 Memantine, 611
 Memory, 223, 233, 321, 519
 Memory processing, 363
 Meprobamate, 465
 Mepyramine, 683
 Mesopontine, 163
 Metabotropic glutamate receptors, 439
 Methamphetamine, 705
 Methiothepin, 677
 5-Methoxy-*N,N*-dimethyltryptamine, 75
 3,4-Methylenedioxymethamphetamine (MDMA), 223
 Mianserin, 677
 Mice, 339, 389, 503, 519
 Microdialysis, 15, 183, 345, 369, 659
 Microphysiometry, 719
 MK-801, 611
 Mocllobemide, 649
 Monoamine oxidase-A, 1
 Morphine, 43, 53, 419
 gender differences, 91
 reinforcing properties, 91
 Morris maze, 105
 Motor activity, 439
 MPTP, 425
 MSOPPE, 439
 Muscarinic, 163
 Naloxone, 621
 Naltrexone, 333, 697
 Naltrindole, 145
 NAN 190, 677
 Neonatal, 563, 711
 Neuroleptic, 433
 Neuropathic pain, 141
 Neuroprotection, 425
 Neurotoxicity, 233, 449
 Nicotine, 191, 247, 665, 711
 Nitric oxide, 199
 7-Nitroindazole, 199
 Nitrous oxide antinociception, 217
 NMDA receptors, 39, 67, 439, 659, 743
N-Methyl-D-aspartate, 621
 Nociception, 621
 Noradrenaline, 223, 539, 591
 NREM sleep, 155
 Nucleus accumbens, 345, 659
 Olfactory learning, 321
 Open field, 7, 585
 Operant behavior, 247, 553, 611
 Opiates, 465, 563
 gender differences, 91
 reinforcing properties, 91
 δ-Opioid antagonists, 145
 Opioid peptides, 217
 κ-Opioid receptors, 261
 μ-Opioid receptors, 261
 Opioids, 333, 489, 697
 P and NP lines of rats, 691
 Pain, 621
 Palatability, 97
 Panic, 571
 Parkinsonism, 523
 Parkinson's disease, 425, 503
 Passive-avoidance learning, 223
 Pavlovian conditioning, 509
 PBN, 425
 PD-135, 158, 459
 Pentylenetetrazol (PTZ), 23
 Pentylenetetrazole, 475, 743
 Peptidase inhibitors, 217
 Performance, 665
 Pharmacokinetics, 191, 289, 327
 Phencyclidine, 449
 Phentermine, 369
 PHNO, 495
 Physical dependence, 563
 Physostigmine, 175
 Pigs, 123
 Pilocarpine, 547
 Plus-maze test, 199, 465
 PNU-99194A, 31
 PPTg, 267
 Pregnancy, 105
 Prenatal morphine, 39
 Prenatal protein malnutrition, 105
 Prepulse inhibition, 449
 Pretreatment, 175
 Protein restriction, 105
 Protohypericin, 627
 Pruritus, 333
 Pseudohypericin, 627
 Quinine, 357
 Raclopride, 635, 671
 Radical scavenger, 425
 Rat behavior, 351
 Rat model of psychosis, 459
 Rat strain, 141
 Rat thigmotaxis, 209
 Rats, 15, 23, 75, 83, 97, 105, 131, 183, 247, 267, 275, 281, 333, 381, 389, 503, 509, 553, 563, 611, 621, 659, 665, 719, 725
 Rearing, 495
 Recognition, 321
 Reinforcement, 433

- Relapse, 489
REM sleep, 155
Repeated cold stress, 261
Reward, 407
Rewarding properties, 327
Ricinus communis, 577
Rigidity, 523
[³H]Ro 15-1788, 743
Ropinirole, 503
Rotarod, 7, 475
Rotation, 553
- S*-Adenosyl-L-methionine, 523
Saccharin, 357
Salicylate trapping, 425
SCH-23390, 635, 671
Schizophrenia, 449
Scopolamine, 175
SDZ EAA 494, 611
Secretogranin II, 399
Seizures, 39, 577, 677, 743
Selegiline, 649
Self-administration, 289, 399, 489, 563
Self-stimulation, 375, 407
Sensitization, 495, 659, 705
Sensorimotor, 449
Sensory, 433
Serotonin, 1, 15, 75, 145, 183, 233, 509, 531, 591, 731
- Sex differences, 53, 671
Sham-feeding preparation, 635
Shuttle-box avoidance, 23
Sleep homeostasis, 155
Sleep-wake cycle, 155
Social interaction, 7, 267
Soman, 175
Spinal cord, 621
Spiradoline, 97
Squirrel monkeys, 43
SSRIs, 339
Staircase test, 553
Startle, 449
Step-through passive-avoidance task, 519
Stereotypy, 389
Stimulants, 655
Stimulus detection, 665
Strain differences, 743
Stress, 495, 509, 539, 591
Striatum, 389, 547
Subchronic, 175
Sucrose, 97, 697
Swiss mice, 465
Synaptosomes, 1
- Tail flick test, 97, 621
Taste, 599
Taurine, 345
TCDD, 381
- Testosterone, 327, 731
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, 381
TFMPP, 677
Tiagabine, 351
Tolerance, 563, 611
Trait anxiety, 35
Tremors, 117, 503, 523
Tricyclic antidepressants, 339, 599
Turning behavior, 203
- U69, 593
Urocortin, 123
- Vaccine, 191
Ventral tegmental area, 375
Ventromedial tegmentum, 503
- Water maze, 105
Weak training, 223
Wet dog shakes, 39
Wheel running, 585
Wistar Kyoto, 357
Withdrawal, 407
Within-session antagonists, 433
Working memory, 725
- Zolpidem, 351
Zucker rat, 719